Operating Lease, Payments in USD of Seres Therapeutics, Inc. from Q1 2019 to Q3 2025

Taxonomy & unit
us-gaap: USD
Description
Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.
Summary
Seres Therapeutics, Inc. quarterly/annual Operating Lease, Payments history and change rate from Q1 2019 to Q3 2025.
  • Seres Therapeutics, Inc. Operating Lease, Payments for the quarter ending September 30, 2025 was $4.84M, a 9.83% decline year-over-year.
  • Seres Therapeutics, Inc. Operating Lease, Payments for the twelve months ending September 30, 2025 was $17.6M, a 3.99% decline year-over-year.
  • Seres Therapeutics, Inc. annual Operating Lease, Payments for 2024 was $17.3M, a 10.7% increase from 2023.
  • Seres Therapeutics, Inc. annual Operating Lease, Payments for 2023 was $15.7M, a 100% increase from 2022.
  • Seres Therapeutics, Inc. annual Operating Lease, Payments for 2022 was $7.81M, a 14.5% increase from 2021.
Operating Lease, Payments, Trailing 12 Months (USD)
Operating Lease, Payments, Quarterly (USD)
Operating Lease, Payments, YoY Quarterly Change (%)
Operating Lease, Payments, Annual (USD)
Operating Lease, Payments, YoY Annual Change (%)

Seres Therapeutics, Inc. Quarterly Operating Lease, Payments (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q3 2025 $17.6M $4.84M -$527K -9.83% Jul 1, 2025 Sep 30, 2025 10-Q 2025-11-05
Q2 2025 $18.1M $4.84M -$524K -9.77% Apr 1, 2025 Jun 30, 2025 10-Q 2025-08-06
Q1 2025 $18.6M $4.88M +$1.28M +35.7% Jan 1, 2025 Mar 31, 2025 10-Q 2025-05-07
Q4 2024 $17.3M $3.01M -$960K -24.2% Oct 1, 2024 Dec 31, 2024 10-K 2025-03-13
Q3 2024 $18.3M $5.36M +$965K +21.9% Jul 1, 2024 Sep 30, 2024 10-Q 2025-11-05
Q2 2024 $17.3M $5.36M +$1.49M +38.3% Apr 1, 2024 Jun 30, 2024 10-Q 2025-08-06
Q1 2024 $15.8M $3.6M +$183K +5.36% Jan 1, 2024 Mar 31, 2024 10-Q 2025-05-07
Q4 2023 $15.7M $3.97M +$1.54M +63.5% Oct 1, 2023 Dec 31, 2023 10-K 2025-03-13
Q3 2023 $14.1M $4.4M +$2.46M +127% Jul 1, 2023 Sep 30, 2023 10-Q 2024-11-13
Q2 2023 $11.7M $3.88M +$2.54M +191% Apr 1, 2023 Jun 30, 2023 10-Q 2024-08-13
Q1 2023 $9.11M $3.41M +$1.3M +61.5% Jan 1, 2023 Mar 31, 2023 10-Q 2024-05-08
Q4 2022 $7.81M $2.43M -$906K -27.2% Oct 1, 2022 Dec 31, 2022 10-K 2025-03-13
Q3 2022 $8.72M $1.94M +$312K +19.2% Jul 1, 2022 Sep 30, 2022 10-Q 2023-11-02
Q2 2022 $8.4M $1.33M +$1.09M +444% Apr 1, 2022 Jun 30, 2022 10-Q 2023-08-08
Q1 2022 $7.32M $2.11M +$495K +30.6% Jan 1, 2022 Mar 31, 2022 10-Q 2023-05-09
Q4 2021 $6.82M $3.33M Oct 1, 2021 Dec 31, 2021 10-K 2024-03-05
Q3 2021 $1.63M Jul 1, 2021 Sep 30, 2021 10-Q 2022-11-02
Q2 2021 $245K Apr 1, 2021 Jun 30, 2021 10-Q 2022-08-03
Q1 2021 $1.62M Jan 1, 2021 Mar 31, 2021 10-Q 2022-05-04
Q4 2019 $6.51M $1.58M Oct 1, 2019 Dec 31, 2019 10-K 2022-03-01
Q3 2019 $1.65M Jul 1, 2019 Sep 30, 2019 10-Q 2019-11-05
Q2 2019 $1.65M Apr 1, 2019 Jun 30, 2019 10-Q 2019-08-06
Q1 2019 $1.64M Jan 1, 2019 Mar 31, 2019 10-Q 2019-05-02

Seres Therapeutics, Inc. Annual Operating Lease, Payments (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed
2024 $17.3M +$1.67M +10.7% Jan 1, 2024 Dec 31, 2024 10-K 2025-03-13
2023 $15.7M +$7.85M +100% Jan 1, 2023 Dec 31, 2023 10-K 2025-03-13
2022 $7.81M +$988K +14.5% Jan 1, 2022 Dec 31, 2022 10-K 2025-03-13
2021 $6.82M +$519K +8.24% Jan 1, 2021 Dec 31, 2021 10-K 2024-03-05
2020 $6.3M -$212K -3.26% Jan 1, 2020 Dec 31, 2020 10-K 2023-03-07
2019 $6.51M Jan 1, 2019 Dec 31, 2019 10-K 2022-03-01
* An asterisk sign (*) next to the value indicates that the value is likely invalid.